(Q46850363)

25 December 2017

title

Metastatic osteosarcoma (English)

1 reference

25 December 2017

9

William H Meyer

1 reference

25 December 2017

author name string

Najat C Daw

1

1 reference

25 December 2017

Catherine A Billups

2

1 reference

25 December 2017

Carlos Rodriguez-Galindo

3

1 reference

25 December 2017

M Beth McCarville

4

1 reference

25 December 2017

Bhaskar N Rao

5

1 reference

25 December 2017

Alvida M Cain

6

1 reference

25 December 2017

Jesse J Jenkins

7

1 reference

25 December 2017

Michael D Neel

8

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

25 December 2017

published in

Cancer

1 reference

25 December 2017

volume

106

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

403-412

1 reference

25 December 2017

Acute and cumulative effects of carboplatin on renal function

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

Osteogenic sarcoma with clinically detectable metastasis at initial presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Lack of age-dependent cisplatin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

cis-Platinum ototoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Hearing loss in children receiving cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

cis-platinum ototoxicity in children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Comparative adverse effect profiles of platinum drugs.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Antagonistic effect of amphotericin B on carboplatin antitumor activity in human osteosarcoma xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Results of NCI-sponsored phase I trials with carboplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Ifosfamide and exacerbation of cisplatin-induced hearing loss

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Synchronous multifocal osteosarcoma: results in twelve patients treated with neoadjuvant chemotherapy and simultaneous resection of all involved bones

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

FDA drug approval summaries: oxaliplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21626

7 January 2021

Identifiers

DOI

10.1002/CNCR.21626

1 reference

25 December 2017

1 reference

25 December 2017